HomeNewscoronavirusVirologist Dr Shahid Jameel on COVID-19: "We have to get used to this way of life for the next few years"

Virologist Dr Shahid Jameel on COVID-19: "We have to get used to this way of life for the next few years"

Cases in India are rising very quickly – about 195,000 cases were reported on January 11. Over the next 2-4 weeks, there would possibly be a peak

January 13, 2022 / 12:33 IST
Story continues below Advertisement
Dr Shahid Jameel says that hospitals look better prepared and equipped than in the Second Wave, but the biggest challenge for them would be healthcare workers getting infected.
(Illustration: Suneesh Kalarickal)
Dr Shahid Jameel says that hospitals look better prepared and equipped than in the Second Wave, but the biggest challenge for them would be healthcare workers getting infected. (Illustration: Suneesh Kalarickal)

Dr Shahid Jameel is a leading Indian virologist and academic. Currently, he is the Sultan Qaboos bin Said Fellow at Oxford Centre for Islamic Studies and Research Fellow, Green Templeton College, University of Oxford. Dr Jameel has been Chief Executive Officer of the Wellcome Trust/DBT India Alliance, an independent public charity that funds research in health and biomedical sciences in India, since April 2013.

Prior to joining the India Alliance, he was Group Leader of Virology at the International Centre for Genetic Engineering and Biotechnology, New Delhi, for over 25 years. He did his PhD in Biochemistry from Washington State University (USA) and his postdoctoral work in Molecular Virology from the University of Colorado Medical School (USA).

Story continues below Advertisement

Last May, Dr Jameel had resigned as head of India's virus genome sequencing group. In an opinion piece written for the New York Times, he said that "scientists were facing stubborn-resistance to evidence-based policy-making".

In an interview with Moneycontrol, Dr Jameel looks at various aspects of the coronavirus pandemic, Omicron and new variants that may crop up. Excerpts from the interview:

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show